Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.0679 | 0.4927 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0078 | 0.0186 | 0.0728 |
Leishmania major | oxidoreductase-like protein | 0.0085 | 0.0246 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1148 | 0.8628 | 0.8602 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1148 | 0.8628 | 0.8602 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1148 | 0.8628 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.1148 | 0.8628 | 0.5 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.1322 | 1 | 1 |
Schistosoma mansoni | Replicative DNA helicase | 0.1322 | 1 | 1 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.1322 | 1 | 1 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0078 | 0.0186 | 0.0377 |
Wolbachia endosymbiont of Brugia malayi | replicative DNA helicase | 0.1322 | 1 | 1 |
Mycobacterium ulcerans | 3-alpha-hydroxysteroid dehydrogenase | 0.0085 | 0.0246 | 0.0061 |
Loa Loa (eye worm) | oxidoreductase | 0.0078 | 0.0186 | 0.0728 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0085 | 0.0246 | 0.0061 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0085 | 0.0246 | 1 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0085 | 0.0246 | 0.0061 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0078 | 0.0186 | 0.5 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0078 | 0.0186 | 0.0728 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.1322 | 1 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.1148 | 0.8628 | 0.8602 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0085 | 0.0246 | 0.0061 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0078 | 0.0186 | 0.0728 |
Plasmodium vivax | multidrug resistance-associated protein 1, putative | 0.0288 | 0.1846 | 0.1966 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0078 | 0.0186 | 0.0186 |
Mycobacterium leprae | PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase | 0.1322 | 1 | 1 |
Loa Loa (eye worm) | twinkle helicase | 0.0378 | 0.2552 | 1 |
Leishmania major | pteridine reductase 1 | 0.0085 | 0.0246 | 1 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.1148 | 0.8628 | 0.8602 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0085 | 0.0246 | 1 |
Onchocerca volvulus | 0.0085 | 0.0246 | 1 | |
Schistosoma mansoni | dihydropteridine reductase | 0.0078 | 0.0186 | 0.0186 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0078 | 0.0186 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0078 | 0.0186 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1148 | 0.8628 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.1148 | 0.8628 | 0.8602 |
Toxoplasma gondii | 2,4-dienoyl CoA reductase 2, peroxisomal family protein | 0.0085 | 0.0246 | 0.0071 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0078 | 0.0186 | 0.0377 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0679 | 0.4927 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0085 | 0.0246 | 0.0061 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1148 | 0.8628 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 31 uM | Cytotoxicity against human MT4 cells | ChEMBL. | 26119992 |
MIC (functional) | = 25 ug ml-1 | Antimycobacterial activity against p-aminosalicylic acid/isonicotinic acid hydrazide/etambutol/rifampicin-resistant Mycobacterium tuberculosis Spec. 210 | ChEMBL. | 26119992 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.